Company registration number SC730893 (Scotland)
JOHNER MEDICAL UK LIMITED
FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 APRIL 2025
PAGES FOR FILING WITH REGISTRAR
JOHNER MEDICAL UK LIMITED
CONTENTS
Page
Balance sheet
1
Notes to the financial statements
2 - 5
JOHNER MEDICAL UK LIMITED
BALANCE SHEET
AS AT
30 APRIL 2025
30 April 2025
- 1 -
2025
2024
Notes
£
£
£
£
Current assets
Debtors
3
4,467
1,915
Cash at bank and in hand
24,050
17,519
28,517
19,434
Creditors: amounts falling due within one year
4
(20,545)
(18,771)
Net current assets
7,972
663
Capital and reserves
Called up share capital
2
2
Profit and loss reserves
7,970
661
Total equity
7,972
663

The director of the company has elected not to include a copy of the profit and loss account within the financial statements.true

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved and signed by the director and authorised for issue on 12 December 2025
Ms M Rozhdestvenskaya
Director
Company Registration No. SC730893
JOHNER MEDICAL UK LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 APRIL 2025
- 2 -
1
Accounting policies
Company information

Johner Medical UK Limited is a private company limited by shares incorporated in Scotland. The registered office is Level 5, 9 Haymarket Square, Edinburgh, United Kingdom, EH3 8RY.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary a mounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.2
Going concern

The director has considered the ongoing risks associated with the company. This includes an assessment of current inflationary pressure impacting costs and a review of the company's forecasts and cash flow projections for the next 12 months period in order to review available finance resources. The company's ability to continue normal trading operations is dependent on continued financial support from its parent entity, from which a letter of support has been obtained.

1.3
Turnover

Turnover is recognised at the fair value of the consideration received or receivable for goods and services provided in the normal course of business, and is shown net of VAT and other sales related taxes. The fair value of consideration takes into account trade discounts, settlement discounts and volume rebates.

Turnover is generated from consulting and acting as an authorised representative for manufacturers of medical devices.

1.4
Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

1.5
Financial instruments

The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

JOHNER MEDICAL UK LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 APRIL 2025
1
Accounting policies
(Continued)
- 3 -
Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Classification of financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

Basic financial liabilities

Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future paymen ts discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. A m ounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

1.6
Equity instruments

Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.

1.7
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

JOHNER MEDICAL UK LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 APRIL 2025
1
Accounting policies
(Continued)
- 4 -
Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the profit and loss account, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset when the company has a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.

1.8
Foreign exchange

Transactions in currencies other than pounds sterling are recorded at the rates of exchange prevailing at the dates of the transactions. At each reporting end date, monetary assets and liabilities that are denominated in foreign currencies are retranslated at the rates prevailing on the reporting end date. Gains and losses arising on translation in the period are included in profit or loss.

2
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2025
2024
Number
Number
Total
1
2
3
Debtors
2025
2024
Amounts falling due within one year:
£
£
Trade debtors
3,547
667
Corporation tax recoverable
7
-
0
Other debtors
913
1,248
4,467
1,915
JOHNER MEDICAL UK LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 APRIL 2025
- 5 -
4
Creditors: amounts falling due within one year
2025
2024
£
£
Trade creditors
-
0
624
Amounts owed to group undertakings
6,440
6,440
Corporation tax
1,998
272
Other creditors
12,107
11,435
20,545
18,771
5
Audit report information

As the income statement has been omitted from the filing copy of the financial statements, the following information in relation to the audit report on the statutory financial statements is provided in accordance with s444(5B) of the Companies Act 2006:

The auditor's report was unqualified.

Statutory Auditor:
Azets Audit Services
6
Parent company

The immediate parent company is Johner Medical GmbH, a company registered in Germany.

The ultimate parent undertaking is Johner Holding GmbH, a company registered in Germany.

2025-04-30 2024-05-01 false false false 19 December 2025 CCH Software CCH Accounts Production 2025.300 No description of principal activity Ms M Rozhdestvenskaya MFMAC Secretaries Limited SC730893 2024-05-01 2025-04-30 SC730893 2025-04-30 SC730893 2024-04-30 SC730893 core:CurrentFinancialInstruments core:WithinOneYear 2025-04-30 SC730893 core:CurrentFinancialInstruments core:WithinOneYear 2024-04-30 SC730893 core:CurrentFinancialInstruments 2025-04-30 SC730893 core:CurrentFinancialInstruments 2024-04-30 SC730893 core:ShareCapital 2025-04-30 SC730893 core:ShareCapital 2024-04-30 SC730893 core:RetainedEarningsAccumulatedLosses 2025-04-30 SC730893 core:RetainedEarningsAccumulatedLosses 2024-04-30 SC730893 bus:Director1 2024-05-01 2025-04-30 SC730893 2023-05-01 2024-04-30 SC730893 bus:PrivateLimitedCompanyLtd 2024-05-01 2025-04-30 SC730893 bus:SmallCompaniesRegimeForAccounts 2024-05-01 2025-04-30 SC730893 bus:FRS102 2024-05-01 2025-04-30 SC730893 bus:Audited 2024-05-01 2025-04-30 SC730893 bus:CompanySecretary1 2024-05-01 2025-04-30 SC730893 bus:FullAccounts 2024-05-01 2025-04-30 xbrli:pure xbrli:shares iso4217:GBP